FDA 483 - Biocon Generics Inc. - October 10, 2025

During inspections conducted on October 6 and October 10, 2025, the Food and Drug Administration (FDA) issued a Form 483 to a pharmaceutical firm, citing a critical observation regarding the company's adherence to its established procedures for warehousing drug products. The main violation identified was the firm's failure to properly document temperature and humidity monitoring data for its drug product storage area. Specifically, the inspection revealed that while the company recorded temperature and humidity data in a dedicated logbook, entries lacked the required personnel signatures indicating who recorded the data and reviewer signatures verifying the information. This practice contravened the firm's own Standard Operating Procedure (SOP BG.WH.07, Rev No. 04) for warehouse temperature and humidity monitoring. The affected warehouse stores raw materials crucial for manufacturing finished drug products, including SG tablets, HE tablets, and HE capsules. This FDA 483, issued pursuant to Section 704(b) of the Federal Food, Drug, and Cosmetic Act, signifies that observed conditions may indicate non-compliance with regulatory standards. The firm is expected to evaluate these deficiencies, implement comprehensive corrective actions, and ensure strict adherence to its internal quality procedures to prevent recurrence and maintain product quality and safety.